# CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

> **NCT00586391** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 14 (actual)

## Conditions studied

- B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **GENETIC:** CD19CAR-28-zeta T cells
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00586391
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-02
- **Primary completion:** 2014-07
- **Final completion:** 2029-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00586391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00586391, "CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00586391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*